Tetrac delayed the onset of ocular melanoma in an orthotopic mouse model

Osnat Ashur-Fabian, Ofira Zloto, Ina Fabian, Galya Tsarfaty, Martin Ellis, David M. Steinberg, Aleck Hercbergs, Paul J. Davis, Ido Didi Fabian

Research output: Contribution to journalArticlepeer-review


Ocular melanoma research, the most common primary intraocular malignancy in adults, is hindered by limited in vivo models. In a series of experiments using melanoma cells injected intraocularly into mouse eyes, we developed a model for ocular melanoma. Inoculation of 5 × 105 B16F10 cells led to rapid tumor growth, extensive lung metastasis, and limited animal survival, while injection of 102 cells was sufficient for intraocular tumors to grow with extended survival. In order to improve tumor visualization, 102 melanoma cells (B16F10 or B16LS9) were inoculated into Balb/C albino mouse eyes. These mice developed intraocular tumors that did not metastasize and exhibited extended survival. Next, we studied the therapeutic potential of inhibitor of the thyroid hormones-αvβ3 integrin signaling pathway in ocular melanoma. By utilizing tetraiodothyroacetic acid (tetrac), a thyroid hormone derivative, a delay in tumor onset in the B16F10 (integrin+) arm was observed, compared to the untreated group, while in the B16LS9 cells (integrin–) a similar rate of tumor onset was noticed in both experimental and control groups. In summary, following an optimization process, the mouse ocular melanoma model was developed. The models exhibited an extended therapeutic window and can be utilized as a platform for investigating various drugs and other treatment modalities.

Original languageEnglish
JournalFrontiers in Endocrinology
Issue numberJAN
StatePublished - 2019


  • Melanoma
  • Mouse
  • Tetrac
  • Thyroid
  • Αvβ3 integrin


Dive into the research topics of 'Tetrac delayed the onset of ocular melanoma in an orthotopic mouse model'. Together they form a unique fingerprint.

Cite this